To Evaluate the Safety and Efficacy of Intracranial Stent Assisted Endovascular Treatment of Intracranial Aneurysms

Inclusion Criteria: * Aged from 18 to 80 years, male or female; * Patients diagnosed as wide-neck intracranial aneurysms by brain CTA/MRA/DSA (neck width≥4mm or bodyor a dome-to-neck ratio\<2); * Parent vessel with a diameter of ≥2.5mm and ≤4.5mm; * Patients target aneurysm is planned to be embolized using intracranial stent assisted with coiling; * The mRS Score of the patients was 0-2; * Patients understand the purpose of the study, accept the follow-up period, and agree to comply with all requirements, agree to participate in the clinical trial and voluntarily sign the informed consent. Exclusion Criteria: * Patients who have contraindications to antiplatelet and/or anticoagulant therapy or do not start antiplatelet therapy in time before treatment. * Patients with anatomical structure is not suitable for endovascular treatment due to severe vascular tortuosity or stenosis shown by angiography. * Known to be allergic to Nitinol platinum alloy and angiographic agents. * Conditions that in the opinion of the investigators would prevent patients from completing the study, such as the expected survival period of active tumor less than 1-year, high-risk group of cerebral thrombosis, heart failure and atrial fibrillation. * Patients combined moyamoya disease, intracranial tumor, intracranial arteriovenous malformation, intracranial arteriovenous fistula and intracranial hematoma. * The target aneurysm has previously received intravascular embolization or stent implantation treatment; * Multiple aneurysms or complex aneurysms; * Patients with acute ruptured aneurysm; * Serious infection is not controlled and is not suitable for operation; * Patients who underwent major surgery or interventional therapy (such as brain, cardiac, chest, abdominal or peripheral vascular) within 30 days before surgery; * Obvious abnormal coagulation function or bleeding tendency; * Combined with severe renal insufficiency, creatinine greater than or equal to 200umol/L; Patients with severe liver diseases (such as acute and chronic hepatitis, cirrhosis), or ALT more than 3 times the upper normal limit; * Pregnancy, lactation, or women of childbearing age who plan to be pregnant during the study period; * Participation in any other clinical trial within 30 days prior to signing informed consent; * Other conditions considered by the investigator to be inappropriate for enrollment.